<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Aug. 27, 2020 (HealthDay News) — There is no association between use of topical calcineurin inhibitors (TCIs) for the treatment of atopic dermatitis (AD) and an increased risk for skin cancer, according to a study published online Aug. 12 in JAMA Dermatology<\/i>.<\/p>\n
Maryam M. Asgari, M.D., M.P.H., from the Massachusetts General Hospital in Boston, and colleagues used data from Kaiser Permanente Northern California to identify 93,746 adults (\u226540 years) with a physician-rendered diagnosis of AD or dermatitis (diagnosed from 2002 through 2013 with follow-up through 2017). The risk for keratinocyte carcinoma (KC) was compared among adults exposed to TCIs versus those exposed to topical corticosteroids and those unexposed to TCIs or topical corticosteroids.<\/p>\n
The researchers observed no association between TCI exposure and KC risk (adjusted hazard ratio [aHR], 1.02; 95 percent confidence interval [CI], 0.93 to 1.13) versus topical corticosteroid exposure. There were no significant differences noted in basal cell carcinoma (BCC) risk (aHR, 1.01 [95 percent CI, 0.90 to 1.14] for TCI versus topical corticosteroids) or squamous cell carcinoma (SCC) risk (aHR, 0.94 [95 percent CI, 0.82 to 1.08] for TCI versus topical corticosteroids). Findings were similar when comparing individuals with TCI exposure to unexposed individuals (aHR, 1.04 [95 percent CI, 0.91 to 1.19] for BCC). The investigators observed no associations between TCI dose, frequency, and duration of use and BCC, SCC, or overall KC risk.<\/p>\n
“The findings of this study suggest that use of topical calcineurin inhibitors may not increase the risk of keratinocyte carcinoma risk among adults with atopic dermatitis,” the authors write.<\/p>\n
Asgari disclosed financial ties to Valeant Pharmaceuticals and Pfizer.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n